Skip to content

    Dishman Carbogen

    DCAL
    Healthcare·13 Feb 2025
    Management Summary

    Dishman Carbogen Amcis reported a strong Q3 FY25, driven by significant EBITDA growth and improved operating margins. The company is progressing with its French drug product facility, expecting GMP certification soon, and is reinforcing synergies across its global operations. Despite some challenges like increased finance costs due to covenant breaches, management is optimistic about future growth and margin expansion, targeting 24-25% EBITDA margin by FY28.

    Highlights

    7

    • Revenue for Q3 FY25 stood at INR 682 crores.

    • EBITDA for Q3 FY25 was INR 140.6 crores, marking a 230% increase compared to Q3 FY24.

    • Operating margin for Q3 FY25 was 20.6%.

    • Net debt as of December 31, 2024, decreased by CHF 5 million to CHF 168 million.

    • The France subsidiary generated $3 million in revenue and incurred a $1.1 million loss in Q3 FY25, targeting break-even by the next financial year.

    • FY25 revenue guidance is set at over INR 2700 crores, with EBITDA expected to be INR 425-450 crores.

    • Long-term revenue growth is projected at a CAGR of approximately 10% over the next 3-5 years.

    What Changed2

    vs Q4 FY25

    Guidance items16 → 19 (+3)Risks discussed5 → 6 (+1)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹682 Cr
    2. 02EBITDA₹140.6 Cr+2.3%YoY
    3. 03Operating Margin20.6%
    4. 04Profit Before Tax₹27 Cr
    5. 05Finance Cost₹48.78 Cr+47%YoY

    Segment breakdown

    RevenueMargin
    Carbogen Amcis CRAMS₹512 Cr23.7%
    Cholesterol and Vitamin D Analogues₹50.65 Cr14.6%
    India CRAMS₹77.7 Cr—
    India Quats and Generic₹41.5 Cr7.3%
    France Subsidiary₹3 Cr—
    Heatmap· 2 shared metrics

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    USD 20 million

    Debt

    Net CHF 168 million

    Guidance & targets

    19
    CategoryTargetPriority
    Revenue
    FY25 Revenue
    INR 2700 crores+
    		High
    Revenue
    Revenue Growth CAGR
    10%
    		High
    Revenue
    France Subsidiary Revenue
    $9 million
    		High
    Revenue
    France Subsidiary Revenue
    $18 million
    		High
    Revenue
    ADC Commercial Revenue
    $15-20 million
    		Medium
    Revenue
    ADC Development Revenue
    $15-20 million
    		Medium
    Profitability
    FY25 EBITDA
    INR 425-450 crores
    		Medium
    Profitability
    Next Year EBITDA
    INR 500 crores+
    		High
    Profitability
    France Subsidiary Break-even
    Break-even
    		High
    Margin
    Next Year EBITDA Margin
    20%
    		High
    Margin
    FY27 EBITDA Margin
    22%
    		Medium
    Margin
    FY28 EBITDA Margin
    24-25%
    		Medium
    Debt
    Net Leverage Ratio
    <2 (1.5 to 2)
    		High
    Capex
    Annual Capex
    $20-25 million
    		High
    Finance Cost
    Interest Cost Reduction
    INR 10 crores
    		High
    Finance Cost
    Interest Cost Level
    INR 30 crores
    		High
    Product Pipeline
    ADC Commercial Production
    Resume
    		High
    Tax
    FY25 Tax Expense
    INR 40 crores
    		High
    Tax
    Next Year Tax Rate
    Much better percentage
    		Medium

    France Subsidiary Break-even

    Next Financial Year
    CurrentLoss of $1.1 million in Q3 FY25
    TargetBreak-even

    Why it matters

    Achievement of break-even for the new French facility is a key milestone for profitability and return on investment.

    And in the next year, what we expect is we should be closer to about 18 million, and that would mean that we would be breaking even in the next financial year.

    How to verify

    key_financials.segment_breakdown[name='France Subsidiary'].metrics[label='Loss']

    Risks & concerns

    6
    RiskSeverity

    Competition in Vitamin D analogues

    The Netherlands business faced difficult competition, especially around the vitamin D analogues family of products. — Management acknowledged

    medium

    Foreign Exchange Fluctuation

    Foreign exchange fluctuation, particularly the Indian rupee depreciating against the Swiss franc, impacted employee expenses. — Management acknowledged

    low

    Breach of Financial Covenants

    Breach of financial covenants with banking syndicate led to a step-up in interest costs, though performance improvement is expected to mitigate this. — Management acknowledged

    medium

    Delay in French Facility Operations

    Technical issues and equipment corrections caused a delay in the start of operations for the French entity, impacting Q4 FY24 financials. — Management acknowledged

    low

    Capacity Bottlenecks

    Global capacity bottlenecks, especially across Europe, limited the ability to cope with higher demand and pursue aggressive growth. — Management acknowledged

    low

    Attrition Rate in Phase III to Commercial

    Only about 10% of Phase III projects typically go commercial, implying a need for a robust development pipeline. — Management acknowledged

    low

    Q&A highlights

    8

    “What we focus on is the operating profit. And as I already mentioned in my presentation, the finance cost in this particular quarter has increased significantly as compared to the previous quarter. So that was the major reason why the profit before tax was lower in this quarter as compared to the previous one.”

    Clarified that the lower PBT was due to higher finance costs, not operational issues, and that operating profit is the key focus.

    asked by Priyanka Patel

    2 min read6 chapters

    Detailed Narrative

    01

    Q3 FY25 Financial Performance Highlights

    Dishman Carbogen Amcis delivered a robust Q3 FY25, reporting INR 682 crores in revenue. The company's EBITDA surged by 230% YoY to INR 140.6 crores, with an operating margin of 20.6%. For the nine months ended December 31, 2024, revenue reached INR 1,995 crores, a modest increase from INR 1,961 crores in the prior year, while 9M EBITDA grew by 37.2% to INR 318.5 crores.

    02

    Segmental Performance and Strategic Focus

    The Carbogen Amcis CRAMS segment achieved a 23.7% margin in Q3 FY25. India CRAMS demonstrated strong growth, with Q3 revenue up 28.5% YoY to INR 77.7 crores and 9M revenue up 61% YoY to INR 209 crores. The Netherlands business, focused on cholesterol and vitamin D analogues, faced competition but is seeing improved order flow. Management highlighted a strategic focus on early-phase projects for Carbogen Amcis to drive future growth.

    03

    Operational Milestones and Leadership Transition

    The new drug product facility in France successfully completed its audit and is awaiting official GMP certification, a significant milestone. Similarly, the Chinese affiliate has been audited for local certification to pursue business in the Chinese pharmaceutical market. Pascal Villemagne announced his departure as CEO of Carbogen Amcis, effective March 31, 2025, and will be succeeded by Dr. Stephan Fritschi, a long-standing company veteran.

    04

    Debt Management and Finance Cost Outlook

    Net debt reduced by CHF 5 million to CHF 168 million as of December 31, 2024. The company previously breached financial covenants, leading to a temporary increase in finance costs, which stood at INR 48.78 crores in Q3 FY25. However, with improved performance, management expects interest costs to reduce by approximately INR 10 crores from Q4 FY25, targeting around INR 30 crores within a couple of quarters. The long-term goal is to reduce net leverage to between 1.5 and 2 within three years.

    05

    Future Growth and Margin Expansion Targets

    Management provided an optimistic outlook, guiding for FY25 revenue to exceed INR 2700 crores and EBITDA to be in the range of INR 425-450 crores. For the next financial year, EBITDA is projected to surpass INR 500 crores with a 20% margin. The company aims for a long-term revenue CAGR of approximately 10% over the next 3-5 years, with EBITDA margins potentially reaching 22% by FY27 and 24-25% by FY28, driven by improved India performance.

    06

    ADC and Bioconjugation Strategy

    Dishman Carbogen Amcis is actively involved in bioconjugation projects beyond ADCs, with current development revenues for ADCs being in the range of $15-20 million. Commercial production for ADCs is anticipated to resume in 2026-2027, potentially generating $15-20 million in revenue. However, the company is not currently pursuing peptide or GLP-1 production due to the significant capital expenditure and specialized knowledge required, which are not core to its current business model.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.